| 000 | 01731 a2200457 4500 | ||
|---|---|---|---|
| 005 | 20250516203155.0 | ||
| 264 | 0 | _c20150709 | |
| 008 | 201507s 0 0 fre d | ||
| 022 | _a2214-8116 | ||
| 024 | 7 |
_a10.1016/j.jmv.2014.02.001 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aMeddahi, S | |
| 245 | 0 | 0 |
_a[Pharmacologic and clinical characteristics of direct inhibitors of factor Xa: rivaroxaban, apixaban, edoxaban and betrixaban]. _h[electronic resource] |
| 260 |
_bJournal des maladies vasculaires _cMay 2014 |
||
| 300 |
_a183-94 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 |
_aAcute Coronary Syndrome _xdrug therapy |
| 650 | 0 | 4 | _aAdministration, Oral |
| 650 | 0 | 4 |
_aAnticoagulants _xpharmacology |
| 650 | 0 | 4 |
_aBenzamides _xpharmacology |
| 650 | 0 | 4 |
_aBlood Coagulation _xdrug effects |
| 650 | 0 | 4 |
_aEmbolism _xprevention & control |
| 650 | 0 | 4 |
_aFactor Xa Inhibitors _xadverse effects |
| 650 | 0 | 4 |
_aHemorrhage _xchemically induced |
| 650 | 0 | 4 |
_aHemostatics _xtherapeutic use |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aMorpholines _xpharmacology |
| 650 | 0 | 4 |
_aPostoperative Complications _xprevention & control |
| 650 | 0 | 4 |
_aPyrazoles _xpharmacology |
| 650 | 0 | 4 |
_aPyridines _xpharmacology |
| 650 | 0 | 4 |
_aPyridones _xpharmacology |
| 650 | 0 | 4 | _aRivaroxaban |
| 650 | 0 | 4 |
_aStroke _xprevention & control |
| 650 | 0 | 4 |
_aThiazoles _xpharmacology |
| 650 | 0 | 4 |
_aThiophenes _xpharmacology |
| 650 | 0 | 4 |
_aThrombophilia _xdrug therapy |
| 650 | 0 | 4 |
_aThrombosis _xprevention & control |
| 700 | 1 | _aSamama, M-M | |
| 773 | 0 |
_tJournal des maladies vasculaires _gvol. 39 _gno. 3 _gp. 183-94 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.jmv.2014.02.001 _zAvailable from publisher's website |
| 999 |
_c23659675 _d23659675 |
||